Welcome to our dedicated page for Perrigo Co Plc news (Ticker: PRGO), a resource for investors and traders seeking the latest updates and insights on Perrigo Co Plc stock.
Perrigo Company plc (NYSE: PRGO) is a leading global provider of over-the-counter (OTC) consumer goods and pharmaceutical products, delivering high-quality healthcare solutions at affordable prices. Established in 1887, Perrigo has grown from a packager of generic home remedies to a top-five global OTC manufacturer and supplier of store-brand infant formulas. Headquartered in Ireland, Perrigo operates across North America, Europe, Australia, Israel, and China.
Perrigo's diverse product portfolio includes private-label consumer health goods sold to major retailers such as Walmart, Amazon, Costco, and CVS. In addition, the company offers branded OTC products, generic extended topical prescription products, and receives royalties from the multiple sclerosis drug Tysabri®.
In recent years, Perrigo has focused on expanding its consumer self-care business. A significant milestone was the FDA approval of Opill®, the first-ever daily birth control pill available OTC in the U.S., which Perrigo began shipping in March 2024. The company's strategic initiatives also include Project Energize, a growth and efficiency program aimed at driving sustainable, value-accretive growth.
Perrigo continues to make strides in the industry, as evidenced by its financial performance and strategic partnerships. The company reported net sales of $1.1 billion for the first quarter of 2024, despite facing challenges such as inventory de-stocking at U.S. retail customers and supply chain constraints. Perrigo's leadership team, including the recent appointment of Roberto Khoury to lead the Consumer Self-Care International segment, is committed to driving innovation and expanding the company's global footprint.
For more information, visit Perrigo's website.
Perrigo Company plc (NYSE: PRGO) announced a 7% increase in its quarterly dividend to $0.26 per share, up from $0.24 per share. This marks the 19th consecutive year of dividend increases. The cash dividend is payable on March 17, 2022 to shareholders of record by February 28, 2022, totaling $1.04 annually. Perrigo, a leader in Quality, Affordable Self-Care Products, remains committed to enhancing consumer well-being through its extensive range of over-the-counter health solutions.
Perrigo Company plc (NYSE; TASE: PRGO) is set to release its fourth quarter and fiscal year 2021 financial results on March 1, 2022, at 8:30 A.M. (EST). A conference call will follow, accessible via webcast on the Perrigo investor relations website. The company is known for its wide range of OTC health and wellness solutions, leading as a store brand OTC player in the U.S. and a top contender in Europe with over 200 branded products across 28 countries. Investors should stay tuned for updates reflecting the company's financial performance and strategic direction.
Perrigo Company plc (NYSE: PRGO) has partnered with Premise Health to enhance its occupational health program by introducing virtual health services for employees outside Michigan. This initiative, launching this month, aims to provide 24/7 access to essential occupational health care via Premise's Digital Wellness Center. Key services include injury evaluation, treatment, and return-to-work strategies. This expansion promotes employee health and aims to increase productivity while reducing healthcare costs.
Perrigo Company plc (NYSE; TASE: PRGO) announced that President and CEO, Murray S. Kessler, will present at the 40th Annual J.P. Morgan Healthcare Conference on January 12, 2022, at 3:45 PM (EST). The virtual presentation can be accessed on the company's website. Perrigo leads in providing quality self-care products and OTC health solutions, holding over 9,000 SKUs under customer brands in the U.S. and being a top OTC company in Europe. More details are available on their website at www.perrigo.com.
Perrigo Company plc (NYSE; TASE: PRGO) announced its voluntary delisting from the Tel Aviv Stock Exchange (TASE) on November 22, 2021, following the divestiture of its Israeli-based operations. The delisting is expected to take effect three months post-request, with shares transitioning to the New York Stock Exchange (NYSE). CEO Murray S. Kessler highlighted this decision as part of Perrigo's significant transformation over the past three years. The company remains committed to its self-care strategy, being a major player in over-the-counter health products.
Perrigo Company plc (NYSE: PRGO) reported its third quarter fiscal 2021 results, revealing net sales of $1.04 billion, a 4.0% increase year-over-year. Organic growth was 2.6% despite challenges including a 5.7 percentage point hit from supply chain disruptions. Adjusted diluted EPS decreased 25.0% to $0.45. The company sees potential in the rebound of its cough/cold business and anticipates adjusted diluted EPS of $2.00 to $2.10 for 2021. Key developments include the completion of the RX business divestiture and acquisition of HRA Pharma.
Perrigo Company plc (NYSE: PRGO) announced that Rolf A. Classon will not seek re-election as Chairman at the annual meeting in May 2022. Orlando D. Ashford, who joined the board in December 2020, is expected to succeed him. Classon, who has served as Chairman since 2018, expressed optimism for Perrigo's future during his tenure, which has seen a transformation into a consumer self-care company. CEO Murray Kessler praised Classon's leadership, while emphasizing Ashford's relevant experience as a benefit for the company moving forward.
Perrigo Company plc (NYSE: PRGO) has declared a quarterly dividend of $0.24 per share, scheduled for payment on December 21, 2021, to shareholders recorded as of December 3, 2021. The company continues to reinforce its position as a leading provider of quality self-care products, appealing to a growing market for affordable health solutions. The dividend announcement highlights Perrigo's ongoing commitment to returning value to its shareholders while maintaining a focus on consumer self-care.
Perrigo Company plc (NYSE; TASE: PRGO) will announce its third quarter 2021 financial results on November 10, 2021, at 8:30 A.M. (EST). A conference call will follow, available via webcast on the company’s investor relations site. Perrigo is a leading provider of self-care products and OTC health solutions, holding a significant market position with over 9,000 SKUs in the U.S. and ranking among the top 10 OTC companies in Europe.
Perrigo Company plc (NYSE: PRGO) has appointed Jim Dillard as the new EVP and President of Consumer Self-Care Americas (CSCA), effective immediately. Dillard, previously EVP and Chief Scientific Officer, will continue reporting to CEO Murray Kessler. The company has completed its transformation to focus on consumer self-care and resolved an Irish tax uncertainty. Kessler emphasized the importance of profitable growth, while Dillard expressed enthusiasm for leveraging innovation and improving margins. Rich Sorota has mutually separated from the company.
FAQ
What is the current stock price of Perrigo Co Plc (PRGO)?
What is the market cap of Perrigo Co Plc (PRGO)?
What products does Perrigo Company plc offer?
Where is Perrigo Company plc headquartered?
What is Project Energize?
What is Opill®?
Who are some of Perrigo's major retail partners?
What is Perrigo's focus in the healthcare market?
What recent changes have occurred in Perrigo's leadership?
How did Perrigo perform financially in Q1 2024?
What is Perrigo's approach to innovation?
How can I learn more about Perrigo Company plc?
